Impact Factor Annals Of Internal Medicine

You're scanning journal metrics for a grant application. So or maybe you're deciding where to submit that paper you've been polishing for six months. Either way, you've landed on Annals of Internal Medicine and you're wondering — what's the impact factor actually telling you?

Easier said than done, but still worth knowing.

Short answer: it's high. Even so, consistently high. But the number alone doesn't tell you whether this is the right home for your work.

Let's unpack what the impact factor really means for Annals, where it sits in the landscape, and what smart researchers actually pay attention to Practical, not theoretical..

What Is Annals of Internal Medicine

Annals of Internal Medicine is the flagship journal of the American College of Physicians (ACP). Published weekly since 1927, it's one of the "big five" general medical journals — alongside NEJM, The Lancet, JAMA, and The BMJ Surprisingly effective..

But here's what makes it distinct: it's unapologetically focused on internal medicine and its subspecialties. Cardiology, gastroenterology, infectious disease, rheumatology, endocrinology — if it lives in the internist's world, it lives in Annals.

The journal publishes original research, systematic reviews, clinical guidelines, position papers, and narrative essays. Now, preventive Services Task Force) recommendations. It's also the official home of the USPSTF (U.S. That last part matters — those guidelines move clinical practice nationwide Less friction, more output..

Not just a research journal

Annals has always positioned itself as a journal for practicing physicians, not just academics. The "In the Clinic" series, "Beyond the Guidelines" debates, and "Annals Graphic Medicine" comics — these aren't afterthoughts. They're deliberate editorial choices to keep the journal readable and relevant at the bedside.

Why the Impact Factor Gets So Much Attention

Impact factor is the metric everyone loves to hate — and everyone still checks.

For Annals of Internal Medicine, the 2023 Journal Citation Reports (released June 2024) lists an impact factor of 39.Think about it: 3. Here's the thing — that's up from 35. 2 in 2022, and 25.Practically speaking, 5 in 2021. So the five-year impact factor sits even higher at 44. 1 It's one of those things that adds up..

What that number actually means

The calculation is straightforward: total citations in 2023 to articles published in 2021 and 2022, divided by the number of citable items published in those two years.

But the inputs matter. A single highly cited guideline or landmark trial can shift the needle. Annals publishes roughly 250–300 citable items per year — original articles, reviews, editorials. The 2021–2022 window captured COVID-era publications, which skewed citation counts across all top medical journals.

So yes, 39.3 is impressive. But it's also inflated by a once-in-a-century pandemic.

How It Compares to the Rest of the Pack

Context changes everything. Here's where Annals landed in the 2023 JCR rankings for "Medicine, General & Internal":

The gap is real. Annals sits in a different tier — call it the "elite specialty-general" tier rather than the "mega-journal" tier Simple as that..

But here's what the raw numbers miss: Annals has a higher cited half-life (over 10 years) than any journal above it except NEJM. That means its articles stay relevant longer. This leads to a review on hypertension management from 2015 is still being cited today. The mega-journals publish more breaking news; Annals publishes more durable clinical knowledge Turns out it matters..

Specialty journals beat it on raw IF

Nature Medicine (87.2), Lancet Respiratory Medicine (102.4), JAMA Oncology (45.3) — specialty journals with narrow scopes often post higher impact factors. That's not a knock on Annals. It's a function of citation density in hot fields Which is the point..

If you're comparing journals for submission, compare within scope. Annals competes with JAMA Internal Medicine (IF 24.Even so, 5), PLOS Medicine (11. Which means 8), and BMJ Medicine (newer, no IF yet). In that company, it's the clear leader.

What Drives Citations at Annals

Not all article types pull equal weight. The citation engine runs on a few predictable fuels:

1. Clinical practice guidelines

The USPSTF recommendations published in Annals are citation magnets. The 2021 colorectal cancer screening guideline alone has over 1,200 citations. The 2022 aspirin for primary prevention update? Similar trajectory.

2. Systematic reviews and meta-analyses

Annals publishes fewer of these than The BMJ or JAMA, but the ones it runs are high-impact. The "Living Systematic Review" series on COVID-19 therapeutics drove massive citation volume in 2021–2022.

3. Landmark randomized trials

Annals doesn't publish as many practice-changing RCTs as NEJM or The Lancet. But when it does — the SPRINT blood pressure trial, the PREDIMED Mediterranean diet study (early publications) — they accumulate citations for decades Turns out it matters..

4. Narrative reviews by known authorities

A commissioned review from a recognized thought leader on a perennial topic (atrial fibrillation management, CKD staging, vaccine hesitancy) will out-cite most original research within three years Turns out it matters..

The Metrics Nobody Talks About

Impact factor gets the headlines. But editors and savvy authors watch other signals:

Acceptance rate

Annals hovers around 5–6% for original research. That's NEJM/Lancet territory. But they desk-reject aggressively — roughly 60% of submissions never see a reviewer. If you get sent for review, your odds improve dramatically Took long enough..

Time to decision

First decision: median 14 days. Final decision (after revision): median 65 days. That's fast for a top-tier journal. The editorial team prioritizes speed without sacrificing rigor — a deliberate choice by Editor-in-Chief Dr. Christine Laine Easy to understand, harder to ignore. Less friction, more output..

Altmetric attention

Annals articles routinely score in the top 1% of all research outputs by Altmetric. The 2023 "Firearm Injury Prevention" position paper hit an Altmetric score of 2,400+. Policy makers, media, and advocacy groups amplify Annals content far beyond academic circles And that's really what it comes down to..

Social media reach

The journal's Twitter/X account (@Annals_IM) has

over 120,000 followers — modest compared to NEJM or The Lancet, but engagement rates (retweets, quote-tweets, click-throughs) consistently rank in the top quartile for medical journals. That said, the audience skews heavily toward practicing internists, guideline developers, and health policy analysts. Now, that matters. A clinician who changes practice based on an Annals article generates downstream citations that no impact factor captures.

Citation half-life

Annals sits at 9.2 years — meaning half its citations come from articles published more than nine years ago. Compare that to Nature Medicine (6.1) or JAMA (7.4). This is the "textbook effect": Annals content enters clinical curricula, guideline algorithms, and board review materials. It gets cited not because it's trendy, but because it's foundational Less friction, more output..

Eigenfactor and Article Influence Score

These metrics weight citations by the prestige of the citing journal. Annals Eigenfactor (0.112) places it in the top 0.5% of all journals. Its Article Influence Score (4.8) beats JAMA Internal Medicine (3.9) and PLOS Medicine (2.7). In plain English: Annals articles get cited by other high-impact journals, not just by each other.

The Submission Calculus

So should you submit? Depends on what you're optimizing for.

Submit to Annals if:

• You have a rigorous systematic review, guideline-adjacent analysis, or pragmatic trial with clear practice implications.
• Your audience is general internists, hospitalists, or primary care physicians.
• You value speed and a fair, transparent review process (reviewer comments are published alongside accepted articles).
• You want your work in the hands of USPSTF panelists, ACP guideline committees, and residency program directors.

Look elsewhere if:

• You're reporting a phase III industry-sponsored drug trial with narrow specialty appeal — NEJM, Lancet, or JAMA will give it wider reach.
• Your work is basic science, translational, or heavily molecular — Annals readers won't cite it.
• You need open access by default. Annals offers hybrid OA ($3,500 APC), but it's not Plan S compliant without institutional agreements.

The Bottom Line

Impact factor is a blunt instrument. But 3 not because it chases citations, but because it publishes what internists use. Annals of Internal Medicine sits at 39.The reviews that settle board exam questions. Here's the thing — the guidelines that change screening ages. The position papers that shape firearm policy, opioid prescribing, and health equity curricula.

If your metric is "will this change how my colleagues practice next year?Also, if your metric is "will this impress my promotion committee? " — check your department's weighting formula. In real terms, " — Annals delivers. Some still worship the raw number. Others have learned to read the fine print.

The journal's tagline — "Clinical excellence. Critical thinking. Which means trusted voice. " — reads like marketing copy. Spend time with its archive, its reviewer reports, its editorial independence statements, and you realize: it's a mission statement. One they've kept for nearly a century Turns out it matters..